BlackRock Amends Protagonist Therapeutics Stake to 4M Shares
Ticker: PTGX · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1377121
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**BlackRock still holds 4M shares of Protagonist Therapeutics as of year-end 2023.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, disclosing its ownership in Protagonist Therapeutics, Inc. As of December 31, 2023, BlackRock reported beneficial ownership of 4,000,000 shares of Protagonist Therapeutics' Common Stock. This represents a significant stake, and changes in BlackRock's holdings can influence investor perception and potentially the stock price of Protagonist Therapeutics.
Why It Matters
BlackRock's updated filing shows its continued, substantial investment in Protagonist Therapeutics, which can signal confidence to other investors and potentially impact the stock's trading activity.
Risk Assessment
Risk Level: low — This filing is a routine update from a major institutional investor and does not indicate any immediate, significant risk to the company or its shareholders.
Analyst Insight
Investors should note BlackRock's continued substantial holding in Protagonist Therapeutics, as it indicates a major institutional investor's ongoing interest, but this filing alone doesn't suggest an immediate buy or sell action.
Key Numbers
- 4,000,000 — Shares Beneficially Owned (This is the total number of Common Stock shares of Protagonist Therapeutics, Inc. that BlackRock Inc. reported owning as of December 31, 2023.)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Protagonist Therapeutics, Inc. (company) — the subject company whose shares are being reported
- 4,000,000 (dollar_amount) — number of shares beneficially owned by BlackRock Inc.
- December 31, 2023 (date) — the date of the event which required the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will maintain a significant stake in Protagonist Therapeutics throughout 2024. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., a major institutional investment manager.
What company's shares are being reported in this filing?
The shares being reported belong to Protagonist Therapeutics, Inc., a pharmaceutical preparations company.
As of what date did the event requiring this filing occur?
The event requiring this filing occurred on December 31, 2023, which is the reporting date for the beneficial ownership.
What is the CUSIP number for the securities reported?
The CUSIP number for the Common Stock of Protagonist Therapeutics, Inc. is 74366E102.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Protagonist Therapeutics, Inc (PTGX).